Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 17, 2021

SELL
$25.12 - $36.89 $502,400 - $737,800
-20,000 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$27.44 - $73.84 $246,960 - $664,560
-9,000 Reduced 31.03%
20,000 $631,000
Q2 2019

Aug 14, 2019

SELL
$40.1 - $52.33 $4,010 - $5,233
-100 Reduced 0.34%
29,000 $1.35 Million
Q1 2019

May 15, 2019

BUY
$40.11 - $53.57 $4,011 - $5,357
100 Added 0.34%
29,100 $1.17 Million
Q4 2018

Feb 14, 2019

BUY
$36.99 - $59.11 $369,900 - $591,100
10,000 Added 52.63%
29,000 $1.33 Million
Q3 2018

Nov 14, 2018

SELL
$40.74 - $51.41 $1.68 Million - $2.12 Million
-41,200 Reduced 68.44%
19,000 $843,000
Q2 2018

Aug 14, 2018

BUY
$36.2 - $76.4 $2.18 Million - $4.6 Million
60,200 New
60,200 $2.36 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $146M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.